

1-Income Statement

Statement of Comprehensive Income	Sch	31-Mar-24	31-Mar-23
		mar-24	mar-23
		COP	COP
INCOME			
Income from operations		14,983,871,029	13,660,346,353
Other income	S 6	1,266,941,325	529,918,719
Changes in inventories		-	-
Total		16,250,812,354	14,190,265,072
Cost of materials	S 24		
Changes in inventories of finished goods and work-in-process	S 24	(756,336,904)	356,935,184
Purchase of products for sale	S 24	7,399,554,227	6,012,444,049
Employee benefit expenses		4,192,705,671	3,968,094,441
Depreciation, amortisation and impairment of non-financial assets		428,888,372	402,945,323
Research and Development expenses			
Other expenses	S 7	3,905,950,064	4,338,107,880
Total		15,170,761,430	15,078,526,876
Operating profit		1,080,050,924	(888,261,804)
Share of profit from equity accounted investments		-	-
Finance costs		-	-
Finance income		-	-
Other financial expenses		-	-
Profit/(Loss) before tax		1,080,050,924	(888,261,804)
Income tax (expense)/credit		(3,048,518,823)	718,478,093
Profit/(Loss) after tax from continuing operations		(1,968,467,899)	(169,783,711)
Post tax profit/ (loss) for the year from discontinued operations		-	-
Profit/(Loss) after tax carried to balance sheet		(1,968,467,899)	(169,783,711)
Profit for the year attributable to:			
Non Controlling Interest			
Owners of the parent		(1,968,467,899)	(169,783,711)
Earnings per share			
Basic earnings per share			
Profit from continuing operations		-	-
Loss from discontinued operations		-	-
Total		-	-
Diluted earnings per share			
Profit from continuing operations		-	-
Loss from discontinued operations		-	-
Total		-	-



Javier Castilla Robles
TP 112 194 -T
Certified Public Accountant

10.Mayo.2024



JOSE JAVIER FONSECA PANCHE
 Professional card # 180 909-T
 Independent Auditor

2-Financial Position

Statement of Financial Position

	Sch	31-Mar-24	31-Mar-23	31-Mar-24	31-Mar-23
		COP IFRS	COP IFRS	INR in Millions IFRS	INR in Millions IFRS
ASSETS					
<i>Current assets</i>					
Inventories		1,875,929,081	1,119,592,178	38	22
Trade receivables	S 8	4,029,844,071	2,865,628,895	81	57
Unbilled revenue		-	-	-	-
Derivative financial instruments		-	-	-	-
Short term investment		-	-	-	-
Other short-term financial assets	S 2	1,330,041,837	809,652,185	27	16
Current tax assets		-	-	-	-
Cash and cash equivalents	S 3	2,230,166,442	2,297,088,973	45	46
Restricted cash		-	-	-	-
Total current assets		9,465,981,432	7,091,962,231	189	142
<i>Non current assets</i>					
Property, plant and equipment		232,213,252	180,163,720	5	4
Goodwill		-	-	-	-
Other Intangible Assets	S 2 B	439,276,055	696,590,781	9	14
Investments accounted for using the equity method		-	-	-	-
Long term financial assets		-	-	-	-
Deferred tax assets		3,978,642,000	6,878,262,000	80	138
Uses Deferred Tax-Current Tax Effect		-	-	-	-
Deferred assets - other		65,440,434	312,663,240	1	6
Restricted cash		-	-	-	-
Total non- current assets		4,715,571,741	8,067,679,741	94	161
Assets and disposal group classified as held for sale		-	-	-	-
Total assets		14,181,553,173	15,159,641,972	284	303
EQUITY AND LIABILITIES					
<i>Liabilities</i>					
<i>Current liabilities</i>					
Provisions		-	-	-	-
Trade payables	S 19	5,459,040,784	4,335,684,484	109	87
Invoices payable with third parties		1,063,939,500	1,242,054,200	21	25
Other local accounts payable		346,216,846	318,347,807	7	6
Other current liabilities	S 5	95,908,143	122,787,317	2	2
Short Term Financial Liabilities	S 30	235,869,156	191,721,522	5	4
Current portion of borrowings		-	-	-	-
Current tax liabilities		-	-	-	-
Total current liabilities		7,200,974,429	6,210,595,329	144	124
<i>Non-current liabilities</i>					
Other liabilities		-	-	-	-
Deferred tax liabilities		-	-	-	-
Total non-current liabilities		-	-	-	-
Liabilities included in disposal group held for sale		-	-	-	-
Total liabilities		7,200,974,429	6,210,595,329	144	124
<i>Equity</i>					
Equity attributable to owners of the parent:					
Share capital	S 4	26,174,737,750	26,174,737,750	523	523
Share Application Money (Pending Allotment)		-	-	-	-
APIC/ Share Premium		-	-	-	-
Retained earnings	S 4	(17,225,691,107)	(17,055,907,396)	(345)	(341)
Profit for the year		(1,968,467,899)	(169,783,711)	(39)	(3)
Reserves & Surplus		-	-	-	-
Currency translation reserve		-	-	-	-
Non Controlling Interest		-	-	-	-
Total Equity		6,980,578,744	8,949,046,643	140	179
Total Equity and Liabilities		14,181,553,173	15,159,641,972	284	303



Javier Castilla Robles
TP 112 194 -T
Certified Public Accountant

10.Mayo.2024



JOSE JAVIER FONSECA PANCHE
Professional card # 180 909-T
Independent Auditor

3-Statement of Cash Flows

Glenmark Pharmaceuticals Colombia SAS
Statement of Cash Flows

Avg
Closing

0.02000
0.02000

	COP	COP	INR In Millions	INR In Millions
	31-Mar-24	31-Mar-23	31-Mar-24	31-Mar-23
(A) Cash flow from operating activities				
Profit before tax	1,080,050,924	(888,261,804)	-39.37	-3.40
<i>Adjustments for non cash items:</i>				
Ammortisation - Brands / Intangibles	389,415,765	379,411,406	7.79	7.59
Depreciation	39,472,607	23,533,917	0.79	0.47
Deferred tax on temporary differences (accounting vs. tax)		18,053,093	0.00	0.36
Non-deductible expenses (Non-recoverable customer values)	98,113,686		1.96	0.00
Impairment of goodwill			0.00	0.00
Rent (unwinding of prepayments arisen on discounting long term security deposits at fair value)			0.00	0.00
Interest expenses			0.00	0.00
Unrealised gain on exchange fluctuation			0.00	0.00
Provision for doubtful debts	-	-		
Cash flows from operations before changes in working capital	1,607,052,982	(467,263,388)	(28.8)	5.0
<i>Changes in operating assets and liabilities</i>				
Non current liabilities, trade payables and other current liabilities	(132,766,903)	488,181,409	-2.66	9.76
Intercompany movement- trade payables	1,123,356,300	1,934,411,604	22.47	38.69
Intercompany movement- other liability	-	-	0.00	0.00
Long term financial assets			0.00	0.00
Trade receivables and unbilled revenue	(1,164,215,176)	(868,074,125)	-23.28	-17.36
Other current assets	(520,389,652)	(172,419,120)	-10.41	-3.45
Inventory Intercompany	(756,336,904)	356,935,184	-15.13	7.14
Inventory Third Party			0.00	0.00
Taxes paid			0.00	0.00
Net cash generated from operating activities	156,700,647	1,271,771,563	(57.8)	39.8
(B) Cash flow from investing activities				
Purchase of property, plant and equipment	(91,522,139)	(194,130,800)	-1.83	-3.88
Purchase of other intangible assets	(132,101,039)	(554,739,645)	-2.64	-11.09
Proceeds from sale of property, plant and equipment				
Dividend received				
Net cash generated from/ (used in) investing activities	(223,623,178)	(748,870,445)	(4.5)	(15.0)
(C) Cash flows from financing activities				
Proceeds from issue of shares				
Proceeds from issue of shares-Intercompany	-	1,587,766,500	0.00	31.76
Pending for Analysis			0.00	0.00
Share Application Money (Pending Allotment)		(567,136,500)	0.00	-11.34
Repayment of borrowings			0.00	0.00
Interest paid on borrowings			0.00	0.00
Dividends paid				
Merger / Demerger and QIP expenses				
Net cash (used in)/ generated from financing activities	-	1,020,630,000	-	20.4
Net change in cash and cash equivalents from continuing operations	(66,922,531)	1,543,531,118	-1.34	30.87
FCTR Adjustments			0.00	0.00
Net change in cash and cash equivalents	(66,922,531)	1,543,531,118	(1.3)	30.9
Cash and cash equivalents at the beginning of the year	2,297,088,973	753,557,855	45.94	15.07
Cash and cash equivalents acquired on merger				
Effect of change in exchange rate on cash and cash equivalents included in disposal group				
Cash and cash equivalents at the end of the year	2,230,166,442	2,297,088,973	44.6	45.9



Javier Castilla Robles
TP 112 194 -T
Certified Public Accountant



JOSE JAVIER FONSECA PANCHE
Professional card # 180 909-T
Independent Auditor

10.Mayo.2024

4-S5 - DTA DTL

S 5

Deferred tax assets and liabilities

Deferred taxes arising from temporary differences and unused tax losses are summarized as follows:

(Amounts in COP)

	31-mar-23	Recognised in other comprehensive income	Recognised in business combination	Adjustment of balances at a rate of 35%	Tax reversal (deferred tax)	Recognised in profit and loss account	Reverse deferred tax years 2017 and 2018	31-mar-24
Deferred tax assets								
Intangible assets								
Property, plants and equipments								
Retirement benefits and other employee benefits								
Straight lining of rent								
Minimum Alternative Tax credit entitlement								
Impact of change on tax rates from previous year								
Unused tax losses	6878262000			555,203,000.00		96,361,000.00	(3,551,184,000.00)	3,978,642,000
Uses Deferred Tax-Current Tax Effect						0.00		-
Others	312,663,240					(247,222,806.00)		65,440,434
Total	7,190,925,240	-	-	555,203,000	-	(150,861,806)		4,044,082,434
Deferred tax liabilities								
Intangible assets								
Other current assets								
Total								
Net deferred tax asset	7,190,925,240	-	-	555,203,000	-	(150,861,806)		4,044,082,434

7-S1 - Prop, Plant & Equipments

Property, plant and equipment

The Group's property, plant and equipment comprise freehold and leasehold land, IT and office equipment, and furniture and fixture. The carrying amount are analysed as follows:

S 1

	Furniture and fixture	Equipment	Vehicles	AS11 Fixed asset	Capital work in progress	Total
Cost						
Balance at 31-03-2023	19,473,250	121,321,339	151,900,000	-	-	292,694,589
- Acquisitions through business combinations						-
- Other acquisitions	86,772,899	4,749,240	-			91,522,139
- Disposals/Transfers						-
- Translation adjustment						-
Balance at 31-3-2024	106,246,149	126,070,579	151,900,000	-	-	384,216,728
Balance at 30-06-2023	106,246,149	126,070,579	151,900,000			384,216,728
-	-	-	-			-
- Acquisitions through business combinations						-
- Other acquisitions						-
- Disposals/Transfers						-
- Translation adjustment						-
Balance at 31-3-2024	106,246,149	126,070,579	151,900,000	-	-	384,216,728
Accumulated Depreciation						
Balance at 31-03-2023	17,858,889	86,254,186	8,417,794	-	-	112,530,869
- Depreciation charge for the year	17,112,433	9,511,750	12,848,424			39,472,607
- Impairment loss recognized						-
- Disposals/Transfers						-
- Translation adjustment						-
Balance at 31-3-2024	34,971,322	95,765,936	21,266,218	-	-	152,003,476
-	34,491,076	95,765,936	21,746,464			
- Depreciation charge for the year	480,246	-	(480,246)	-		-
- Impairment loss recognized						-
- Disposals/Transfers						-
- Translation adjustment						-
Balance at 31-3-2024	34,971,322	95,765,936	21,266,218	-	-	152,003,476
-	34,491,076	95,765,936	21,746,464			152,003,476
-	480,246		(480,246)			

Carrying value

Balance at 31-03-2023	1,614,361	35,067,153	143,482,206	-	-	180,163,720
Balance at 31-3-2024	71,274,827	30,304,643	130,633,782	-	-	232,213,252
Balance at 31-3-2024	71,274,827	30,304,643	130,633,782	-	-	232,213,252

8-S2B-Other Intangible Assets

S 2 B

Other intangible assets

The Group's other intangible assets comprises of acquired computer softwares, website costs and softwares under development. The carrying amounts for the reporting periods under review are analysed as follows:

	Capital work in progress	Brands	B	C	Total
Cost					
Balance at 31-03-2023	1,898,684,012	-	-	-	1,898,684,012
- Internally developed	-				-
- Acquired through business combinations	-				-
- Other acquisitions	132,101,039				132,101,039
- Disposals/ Transfers	-				-
- Translation adjustment	-				-
Balance at 31-3-2024	2,030,785,051	-	-	-	2,030,785,051
- Internally developed					-
- Acquired through business combinations					-
- Other acquisitions					-
- Disposals/ Transfers					-
- Translation adjustment					-
Balance at 31-3-2024	2,030,785,051	-	-	-	2,030,785,051
Amortisation and impairment					
Balance at 31-03-2023	1,202,093,231	-	-	-	1,202,093,231
- Amortisation charge for the year	389,415,765				389,415,765
- Impairment loss					-
- Amotisation charge for dosposals/ transfers					-
- Translation adjustment					-
Balance at 31-3-2024	1,591,508,996	-	-	-	1,591,508,996
- Amortisation charge for the year					-
- Impairment loss					-
- Amotisation charge for dosposals/ transfers					-
- Translation adjustment					-
Balance at 31-3-2024	1,591,508,996	-	-	-	1,591,508,996
Carrying value					
Balance at 31-03-2023	-	-	-	-	521,262,542
Balance at 31-3-2024	439,276,055	-	-	-	439,276,055
Balance at 31-3-2024	439,276,055	-	-	-	439,276,055

5-Schedules 1 de 5

Schedule - S 11
Cost of materials

Particulars	31-Mar-24	31-Mar-23
	COP	COP
	IFRS	IFRS
Finished goods purchased	6,643,217,323	6,369,379,232
Total	6,643,217,323	1,406,949,040

Schedule - S 19
Trade payables

Particulars	31-Mar-24	31-Mar-23
	COP	COP
	IFRS	IFRS
Sundry creditors	5,222,201,412	4,335,684,484
Glenmark India	5,222,201,412	4,335,684,484
Glenmark Argentina	-	-
Advances received / Glenmark Mexico	-	-
Glenmark Perú	-	-
AztraZeneca(Col)		
Unclaimed preference share capital		
Interest accrued but not due		
Employee dues		
Other liabilities		
Total	5,222,201,412.00	4,335,684,484.00

Schedule - S 24
Changes in inventories

Particulars	31-Mar-24	31-Mar-24
	IFRS	IFRS
Opening inventory	1,119,592,178	1,476,527,361
Closing inventory	1,875,929,081	1,119,592,178
Total	(756,336,904)	356,935,184

Schedule - S 24
Cost of materials

6-S 6-Other Current Liabilities

S 6

Other current liabilities

Other current liabilities are summarized as follows:

	31-Mar-24	31-Mar-23
	COP	COP
	IFRS	IFRS
Share Application Money (Pending Allotment)		
Employee dues		
Statutory dues	-	-
Commission payable		
Deferred revenue		
Straight lining of rent		
Others	95,908,143	122,787,317
Invoices payable with third parties		
Values payable for taxes	74,680,909	4,924,780
Estimated liabilities	21,227,234	117,862,537
Customer payments- KAM review	-	-
Others	-	-
Total	95,908,143	122,787,317

9-Comprehensive Income

-

Statement of Comprehensive Income	Sch	31-Mar-24	31-Mar-23
		mar-24	COP
		IFRS	IFRS
Profit for the year		(1,968,467,899)	(169,783,711)
Other comprehensive income:			
Cash flow hedging			
- current year gains (losses)			
- reclassification to profit or loss			
Available-for-sale financial assets			
- current year gains (losses)			
- reclassification to profit or loss			
Exchange differences on translating foreign operations			
Share of other comprehensive income of equity accounted investments			
- reclassification to profit or loss			
Share of other comprehensive income on fair valuation of financial assets/ liabilities			
reclassification to profit or loss			
Income tax relating to components of other comprehensive income			
Other comprehensive income for the period, net of tax			
Total comprehensive income for the period		(1,968,467,899)	(169,783,711)
Total Comprehensive Income attributable to:			
Non Controlling Interest			
Owners of the parent			

10-Statement Changes in Equity

Schedule S 4

Statement of Changes in Equity

[All amounts are stated in Columbian Peso, unless otherwise stated]

	Share Capital	Share Application Money	Capital redemption reserve	Retained earnings	Currency Translation Reserve	Total equity
Balance at 31-03-2023	26,174,737,750		-	(17,225,691,107)	-	8,949,046,643
Dividends				-		-
Dividend tax				-		-
Residual Dividend and Dividend Tax				-		-
Transfer to General Reserve				-	-	-
Lease hold land - Accumulated depn				-		-
Share Application Money (Pending Allotment)				-		-
FCCB Impact				-		-
GPL India ESOP impact				-		-
Transfer of exchange fluctuation reserve				-		-
Transactions with owners				-		-
Profit for the year				(1,968,467,899)		(1,968,467,899)
Other comprehensive income:						-
Cash flow hedging						-
- current year gains (losses)						-
- reclassification to profit or loss						-
Share Premium						-
Available-for-sale financial assets						-
- current year gains (losses)						-
- reclassification to profit or loss						-
Exchange differences on translating foreign operations						-
Share of other comprehensive income of equity accounted investments						-
- reclassification to profit or loss						-
Income tax relating to components of other comprehensive income						-
Total comprehensive income for the year						-
Balance at 31-3-2024	26,174,737,750	-	-	(19,194,159,006)	-	6,980,578,744

12-S2Other Short Trm Fin Assets

Other short term financial assets	31-Mar-24	31-Mar-23
	COP	COP
Particulars	IFRS	IFRS
Cash Collateral		
Input taxes receivables	1,198,386,538	743,281,465
Import advances	-	18,406,928
Others	131,655,299	47,963,792
Total	1,330,041,837	809,652,185
	1,330,041,837	809,652,185

13-S3-Cash & cash equivalents

S 3

Cash and cash equivalents

Cash and cash equivalents include the components as follows:

	31-Mar-24	31-Mar-23
	COP	COP
	IFRS	IFRS
Cash in hand		-
Cash on hand		
Cheques in hand		
Cash in current accounts	2,230,166,442	2,297,088,973
Cash in deposit accounts		
Mutual fund deposit in liquid money market		
Fund-in-transit		
Total	2,230,166,442	2,297,088,973

2,230,166,442 2,297,088,973

-

-

14-S30 Short Term Financial Liabi

Short Term Financial Liabilities

Short Term Financial Liabilities are summarized as follows:

	31-Mar-24	31-Mar-23
	COP	COP
	IFRS	IFRS
Employee dues	235,869,156	191,721,522
Statutory dues		
Commission payable		
Deferred revenue		
Straight lining of rent		
Others		
Total	235,869,156	191,721,522
	235,869,156	191,721,522
	-	-

15-S7 - Inventories

S 7

Inventories

Inventories recognised in the statement of financial position can be analysed as follows:

(Amounts in COP)

Particulars	March 31, 2024	March 31, 2023
Finished Goods	1,875,929,081	1,119,592,178
Others		
Total	1,875,929,081	1,119,592,178
	1,875,929,081	1,119,592,178

16-S 7 - Income Taxes

Income taxes

Tax expense reported in income statement for the years ended :

	LCY	
	31-mar-24	31-mar-23
Current tax expense	-	-
Deferred tax credit	2,899,620,000	(700,425,000)
Uses Deferred Tax-Current Tax Effect	-	-
Deferred assets - other	148,898,823	(18,053,093)
Net tax (expense)/credit	3,048,518,823	(718,478,093)
	-3048518823	718478093
Any adjustments recognised in the period for current tax of previous periods also need to be disclosed separately.	-	-

17-Related Party Transactions

Glenmark Pharmaceuticals Colombia SAS			
Related party transactions			
	COP	INR IN MILLION	USD
Transactions during the year with group companies -			
Share Capital - Purchase of Share by Glenmark India	-	-	
Share Application Money - GPL India	-	-	
Purchases			
Glenmark Pharmaceutical Ltd. - India	2,519,963,468	50.40	622,845.79
Received in warehouse	2,519,963,468	50.40	622,845.79
Inventory in transit	-	-	-
Credit notes	-	-	
Glenmark Pharmaceutical Ltd. Argentina	23,028,176	0.46	5,480.00
Glenmark Pharmaceutical Ltd. Peru			
Bills paid			
Glenmark Pharmaceutical Ltd. - India	826,510,308	16.53	200,696.98
Glenmark Pharmaceutical Ltd. Argentina	22,287,291	0.45	5,480.00
Glenmark Pharmaceutical Ltd. Peru			
Closing Balances- Payable for Purchases			
Glenmark Pharmaceutical Ltd. - India	5,222,201,412	104.44	1,359,186.58
Glenmark Pharmaceutical Ltd. Argentina	-	-	
Glenmark Pharmaceutical Ltd. Peru	-	-	
ONY Biotech Inc (1576 Sweet Home Road Amherst, NY 14228 USA)	236,839,372	4.74	61,640.00
	5,459,040,784		1,420,826.58

2210050101	INDIA	5,222,201,412	5222201412	-
2210050103	OTROS PROVEEDORES EXTERIOR	236,839,372	236839372	-
		5,459,040,784	5,459,040,784	-
		-		-
Trade payables		5,459,040,784	5,459,040,784	-
Diferencia		-	-	-

18-Capital Mgt Pol & Proc.

Capital management policies and procedures

The Group's capital management objectives are:

- a) to ensure the Group's ability to continue as a going concern and
- b) to provide an adequate return to shareholders.

The Group monitors gearing ratio i.e. total debt in proportion to its overall financing structure, i.e. equity and debt. Total debt comprises of all financial liabilities of the Group. The Group manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets.

	31-mar-24	31-mar-23
Total equity	6,980,578,744	8,949,046,643
Total debts	-	-
Overall financing	6,980,578,744	8,949,046,643
Gearing ratio	(0.000)	-

If there are any externally imposed capital requirements, the same are also to be disclosed here.

19-Ratios

Ratios

Particulars	Formula	As at	As at
		March 31, 2024	March 31, 2023
Current Ratio	Current Assets / Current Liabilities	1.31	1.14
Debt-Equity Ratio	Borrowing / Shareholder's Equity	-	-
Debt Service Coverage Ratio	EBIT / (Borrowing + (1+Rate of Interest))	-	-
Return on Equity Ratio	Net Profit / Shareholder's Equity	-28.2%	-1.9%
Inventory turnover ratio	COGS / ((Opening + Closing Inventory)/2)	4.44	4.91
Trade Receivables turnover ratio	Sales / ((Opening + Closing Trade Receivable)/2)	4.35	5.28
Trade payables turnover ratio	Purchases / ((Opening + Closing Trade Payable)/2)	0.38	0.45
Net capital turnover ratio	Net Sales / Shareholder's Equity	2.74	3.15
Net profit ratio	Net Profit / Sales	-13.1%	-1.2%
Return on Capital employed	EBIT / Shareholder's Equity	5.8%	-1.9%
Return on Investment	Net Profit / Shareholder's Equity	-7.5%	-0.6%

21-Note 12 -Share Capital

Glenmark Pharmaceuticals Limited
Notes to the Standalone Financial Statements
(COP-Colombian)

NOTE 12 - EQUITY SHARE CAPITAL

	As at		As at	
	31/03/2024		31/03/2023	
Share capital	No. of Shares	Amount	No. of Shares	Amount
<u>Authorised</u>				
Equity Shares of Re 1 each	275,456	\$ 275,456,000	275,456	\$ 275,456,000
Cumulative redeemable non-convertible preference shares of Rs.100 each	-	-	-	-
<u>Issued, subscribed and fully paid-up equity shares of Re 1 each</u>				
At the beginning of the year	275,456	275,456,000	275,456	275,456,000
Add: Issued during the year	-	-	-	-
At the end of the year	275,456	275,456,000	275,456	275,456,000
		-		275,456,000.00
				-

	31/03/2024		31/03/2023	
	% of Holding	No. of Shares	% of Holding	No. of Shares
<u>List of shareholders holding more than 5 % shares</u>				
Saldanha Family Trust	-	-	-	-

22-Note 14 Trade Payables

Glenmark Pharmaceuticals Limited
Notes to the Standalone Financial Statements
(COP-Colombian)
(ii) TRADE PAYABLES

Particulars	31-mar-24	31-mar-23
Trade payables outstanding dues to Micro, small and medium enterprises under MSMED Act, 2006 [Refer note (i) below]	-	-
Trade payables	5,459,040,784.00	4,335,684,484.00
Invoices payable with third parties	1,063,939,500.00	1,242,054,200.00
Other local accounts payable	346,216,846.04	318,347,806.50
Trade payables outstanding dues to creditors other than micro, small and medium enterprises	-	-
Total	6,869,197,130.04	5,896,086,490.50
	6,869,197,130.04	5,896,086,490.50
	-	-
	-	-

Note (ii)
Ageing Schedule 45382

Particulars	Outstanding for following periods from due of payments #					Total
	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	
(i) MSME		-	-	-		-
Trade payables	1,059,426,235.00	522,749,756.00	1,444,738,727.00	-	2,432,126,066.00	5,459,040,784.00
Invoices payable with third parties	1,063,939,500.00	-	-	-	-	1,063,939,500.00
Other local accounts payable	346,216,846.04	-	-	-	-	346,216,846.04
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
	2,469,582,581.04	522,749,756.00	1,444,738,727.00	-	2,432,126,066.00	6,869,197,130.04
						6,869,197,130.04

Ageing Schedule
Previous year (Mar'22)

Particulars	Outstanding for following periods from due of payments #					Total
	Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	
Trade payables	2,008,967,447.00	662,595,131.00	1,005,491,334.00	180,804,421.00	477,826,151.00	4,335,684,484.00
Invoices payable with third parties	1,560,402,006.50	-	-	-	-	1,560,402,006.50
Other local accounts payable	-	-	-	-	-	-
(i) MSME						-
(ii) Others - Related Parties					-	-
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues - Others	-	-	-	-	-	-
						5,896,086,490.50

Disclosure of Related Party Transactions for the half year ended

31/03/2024

(Amount Lcy'000)

Sr.	Details of the Party (Listed entity/ Subsidiary entering into the transaction)		Details of the counter party			Purchase of Goods and Services (Net of Returns)	Expenses paid on behalf of	Expenses Paid by others on our behalf	In case monies are due to other party as result of transactions	
	Name	PAN/CIN	Name	PAN/CIN	Relationship of the counterparty with the listed entity or its subsidiary				Opening Balance	Closing Balance
1	Glenmark Pharmaceuticals Colombia		Glenmark Pharmaceutical Ltd. - India		Parent Company	2,519,963,468	-		4,335,684	5,222,201
2	Glenmark Pharmaceuticals Colombia		Glenmark Pharmaceutical Ltd. Argentina		Fellow Subsidiary	-			-	-
3	Glenmark Pharmaceuticals Colombia		Glenmark Pharmaceutical Ltd. Peru		Fellow Subsidiary		-		-	-
4	ONY Biotech Inc (1576 Sweet Home Road Amherst, NY 14		ONY Biotech Inc (1576 Sweet Home Road Amherst, NY 14228 USA)			236,839,372				236,839
5										-
6										-
7										-
8										-
9										-
10										-
11									4,335,684	5,459,041

Schedule - L

Long term financial assets

Long term financial assets comprise of the following:

Particulars	31/03/2024	31/03/2023
	COP	COP
	IFRS	IFRS
Held-to-maturity financial assets		
Security deposits assets		
Bonds		
Available-for-sale financial assets		
Investments in listed and unlisted securities		
Others		
Long-term inter company loan		
Investments in Subsidiaries		
Total	-	-

Schedule - M

Trade payables

Particulars	31/03/2024	31/03/2023
	COP	COP
	IFRS	IFRS
Sundry creditors		
Inter Company creditors	5,222,201,412.00	4,335,684,484.00
Acceptances		
Total	5,222,201,412	4,335,684,484
	5,459,040,784.00	4,335,684,484.00
	(236,839,372.00)	-

Particulars	31/03/2024	31/03/2023
	COP	COP
	IFRS	IFRS
Invoices payable with third parties	1,063,939,500.00	1,242,054,200.00
Other local accounts payable	346,216,846.04	318,347,806.50
Total	1,410,156,346	1,560,402,007
	1,410,156,346.04	1,560,402,006.50
	-	-

Schedule - N

Current tax liabilities

Particulars	31/03/2024	31/03/2023
	COP	COP
	IFRS	IFRS
Provision for Wealth Tax		
Provision for Tax		
Total	-	-

Schedule - O

Short-term borrowings

Particulars	31/03/2024	31/03/2023
	COP	COP
	IFRS	IFRS
Short-term borrowings		
Working capital facilities		
Total	-	-

Schedule - P

Current portion of borrowings

Particulars	31/03/2024	31/03/2023
	COP	COP
	IFRS	IFRS
Current portion of long-term borrowings		
Inter Company loan		
Total	-	-

Schedule - Q

Other liabilities

Other current liabilities are summarized as follows:

Particulars	31/03/2024	31/03/2023
	COP	COP
	IFRS	IFRS
Advances received from customer		
Others	95,908,143.00	122,787,316.95
Statutory dues	-	-
Accrued Expenses	-	-
Share Application Money	-	-
Total	95,908,143	122,787,317
	95,908,143.00	122,787,316.95
	-	-

Schedule - R

Short-term financial liabilities

Other current liabilities are summarized as follows:

Particulars	31/03/2024	31/03/2023

	COP	
	IFRS	
Employee dues	235,869,156.00	191,721,522.00
Unclaimed dividend		
Interest accrued but not due		
Others		
Total	235,869,156	191,721,522
	235,869,156.00	191,721,522.00

Schedule - S

Provisions

Particulars	31/03/2024		31/03/2023	
	COP		COP	
	IFRS		IFRS	
Provision for compensated absences				
Provision for gratuity benefit plan				
Provision for Employee benefits				
Total	-	-	-	-

Schedule - T

Long Term Borrowing

Particulars	31/03/2024		31/03/2023	
	COP		COP	
	IFRS		IFRS	
Notes payable				
Term loan from banks				
Inter company loan				
Total	-	-	-	-

Schedule - U

Other liabilities (Non-Current)

Particulars	31/03/2024		31/03/2023	
	COP		COP	
	IFRS		IFRS	
Other liabilities				
Total	-	-	-	-

Schedule - V

Long term financial liabilities

Particulars	31/03/2024		31/03/2023	
	COP		COP	
	IFRS		IFRS	
Security Deposits				
Others				
Total	-	-	-	-

Schedule - W

Equity

Particulars	31/03/2024		31/03/2023	
	COP		COP	
	IFRS		IFRS	
Equity attributable to owners of the parent:				
Share capital	26,174,737,750.00	26,174,737,750.00		
Add- Share issued during the year				
Share Application Money				
Transactions with owners				
Share Premium				
Stock compensation reserve				
<u>Statutory Reserve</u>				
Capital redemption reserve				
Capital reserve				
Amalgamation reserve				
Currency translation reserve				
Reserve & Surplus				
<u>Retained earnings</u>				
Profit & Loss balance	(17,225,691,107.39)	(17,055,907,396.12)		
Addition during the period	(1,968,467,898.91)	(169,783,711.27)		
Current period profit				
Exchnage Fluctuation Reserve				
Components of Defined Employee benefit cost				
Transfer to General reserve				
General reserve	(19,194,159,006.30)	(17,225,691,107.39)		
Non Controlling Interest				
Total Equity	6,980,578,744	8,949,046,643		
	6,980,578,743.70	8,949,046,642.61		

Glenmark Phartmaceuticals Colombia SAS

236,839,372.00

-

Statement of Financial Position	Sch	31/03/2024	31/03/2023
		COP	COP
		IFRS	IFRS
ASSETS			
<i>Current assets</i>			
Cash and cash equivalents	A	2,230,166,442.34	2,297,088,973.40
Restricted cash	B	-	-
Trade receivables	C	4,029,844,071.23	2,865,628,895.18
Inventories	D	1,875,929,081.32	1,119,592,177.54
Other short-term financial assets	E	131,655,298.74	66,370,719.54
Other current assets	F	1,198,386,538.37	743,281,465.46
Total current assets		9,465,981,432.00	7,091,962,231.12
<i>Non current assets</i>			
Property, plant and equipment	G	232,213,251.80	180,163,720.00
Other Intangible Assets	H	439,276,055.00	696,590,781.00
Goodwill	I	-	-
Non-current tax assets	J	-	-
Deferred tax assets	K	3,978,642,000.00	6,878,262,000.00
Uses Deferred Tax-Current Tax Effect		-	-
Deferred assets - other		65,440,433.94	312,663,239.94
Restricted cash	D	-	-
Long term financial assets	L	-	-
Total non - current assets		4,715,571,740.74	8,067,679,740.94
Total assets		14,181,553,172.74	15,159,641,972.06
EQUITY AND LIABILITIES			
<i>Current liabilities</i>			
Trade payables	M	5,222,201,412.00	4,335,684,484.00
Invoices payable with third parties		1,063,939,500.00	1,242,054,200.00
Other local accounts payable		346,216,846.04	318,347,806.50
Current tax liabilities	N	-	-
Short-term borrowings	O	-	-
Current portion of long term borrowings	P	-	-
Other Current liabilities	Q	95,908,143.00	122,787,316.95
Short-term financial liabilities	R	235,869,156.00	191,721,522.00
Provisions	S	-	-
Total current liabilities		6,964,135,057.04	6,210,595,329.45
<i>Non-current liabilities</i>			
Long-term financial liabilities	V	-	-
Deferred tax liabilities	K	-	-
Total non-current liabilities		-	-
Total liabilities		6,964,135,057.04	6,210,595,329.45
Stockholders' equity			
Share capital	W	26,174,737,750.00	26,174,737,750.00
Merger consideration, pending allotment		-	-
Share Premium		-	-
Stock compensation reserve		-	-
Statutory reserve		-	-
Currency translation reserve		-	-
Retained earnings		(17,225,691,107.39)	(17,055,907,396.12)
Addition during the period		(1,968,467,898.91)	(169,783,711.27)
Non Controlling Interest		-	-
Total stockholders' equity		6,980,578,743.70	8,949,046,642.61
Total equity and liabilities		13,944,713,800.74	15,159,641,972.06



Javier Castilla Robles
TP 112 194 -T
Certified Public Accountant



JOSE JAVIER FONSECA PANCHE
Professional card # 180 909-T
Independent Auditor

Glenmark Phartmaceuticals Colombia SAS**Schedule - X****Income from operations**

Particulars	31/03/2024	31/03/2023
	COP	COP
	IFRS	IFRS
Sale of goods and out licensing of Intangible assets	14,983,871,029.24	13,660,346,352.75
other operating revenue		
Income from services		
Total	14,983,871,029.24	13,660,346,352.75
	14,983,871,029.24	13,660,346,352.75

Schedule - Y**Other income**

Other income is summarised as follows:

Particulars	31/03/2024	31/03/2023
	COP	COP
	IFRS	IFRS
Dividend on short term investments		
Profit on sale of short term investments		
Profit on sale of fixed assets		
Exchange Gain		
Profit on Sale of Business		
Miscellaneous income	1,266,941,325.16	529,918,719.08
Total	1,266,941,325.16	529,918,719.08
	1,266,941,325.16	529,918,719.08

Schedule - Z**Material Consumed**

Particulars	31/03/2024	31/03/2023
	COP	COP
	IFRS	IFRS
Consumption of Raw Material		
Consumption of Packing Material		
Total	-	-
	-	-

Schedule - Z**Changes in Inventory of FG and WIP**

Particulars	31/03/2024	31/03/2023
	COP	COP
	IFRS	IFRS
Changes in Inventory of FG and WIP	(756,336,903.78)	356,935,183.62
Total	(756,336,903.78)	356,935,183.62
	(756,336,903.78)	356,935,183.62

Schedule - Z**Purchase of Traded Goods**

Particulars	31/03/2024	31/03/2023
	COP	COP
	IFRS	IFRS
Purchase of Traded Goods	7,399,554,227.02	6,012,444,048.84
Total	7,399,554,227.02	6,012,444,048.84
	7,399,554,227.02	6,012,444,048.84

Glenmark Phartmaceuticals Colombia SAS

Statement of Comprehensive Income	Sch	31/03/2024	31/03/2023
		COP	COP
		IFRS	IFRS
INCOME			
Operating Revenue	X	14,983,871,029.24	13,660,346,352.75
Other income	Y	1,266,941,325.16	529,918,719.08
Total		16,250,812,354.40	14,190,265,071.83
Materials consumed	Z		
Changes in Inventories of FG and WIP		(756,336,903.78)	356,935,183.62
Purchase of Traded Goods		7,399,554,227.02	6,012,444,048.84
Employee benefit expenses	AA	4,192,705,671.00	3,968,094,441.00
Other expenses	AB	3,905,950,063.87	4,338,107,879.64
Depreciation, amortisation and impairment of non-financial assets	AC	428,888,372.20	402,945,323.00
Total		15,170,761,430.31	15,078,526,876.10
Operating profit		1,080,050,924.09	(888,261,804.27)
Finance costs	AD	-	-
Finance income	AE	-	-
Profit/(Loss) before tax		1,080,050,924.09	(888,261,804.27)
Current tax expenses	AF	-	-
Deferred tax expenses	AF	(3,048,518,823.00)	718,478,093.00
Total Tax expenses		(3,048,518,823.00)	718,478,093.00
Profit/(Loss) after tax from continuing operations		(1,968,467,898.91)	(169,783,711.27)



Javier Castilla Robles
TP 112 194 -T
Certified Public Accountant
 10.Mayo.2024



JOSE JAVIER FONSECA PANCHE
 Professional card # 180 909-T
 Independent Auditor

Glenmark Phartmaceuticals Colombia SAS**Schedule - S 1****Property, Plant and Equipment**

Particulars	31/03/2024	31/03/2023
	COP	COP
Gross Block	384,216,728.00	292,694,589.00
less: Accumulated depreciation	152,003,476.20	112,530,869.00
Net Block	232,213,251.80	180,163,720.00
	232,213,251.80	180,163,720.00

Particulars	31/03/2024	31/03/2023
	COP	COP
Capital work in progress		
Total	-	-

Schedule - S 2**Other Intangible assets**

Particulars	31/03/2024	31/03/2023
	COP	COP
Gross Block	2,030,785,051.00	1,898,684,012.00
less: Accumulated depreciation	1,591,508,996.00	1,202,093,231.00
Net Block	439,276,055.00	696,590,781.00
	439,276,055.00	696,590,781.00

Schedule - S 6**Deferred tax liabilities (net)**

Particulars	31/03/2024	31/03/2023
	COP	COP
Deferred tax liabilities (net)		
Deferred tax liability relating to		
Depreciation on tangible and intangible assets	-	-
Deferred tax assets relating to		
Provision for doubtful debts and advances		
Expenses deductible in future years		
Others	4,044,082,434	7,190,925,240
	4,044,082,434	7,190,925,240
Deferred tax liabilities (net)	(4,044,082,434)	(7,190,925,240)
	4,044,082,434	7,190,925,240

Schedule - S 8**Inventories**

Inventories recognised in the statement of financial position can be analysed as follows:

Particulars	31/03/2024	31/03/2023
	COP	COP
Finished goods	1,875,929,081.32	1,119,592,177.54
Goods in transit - Packing material		
Total	1,875,929,081	1,119,592,178
	1,875,929,081.32	1,119,592,177.54